Acutaas Chemicals (ACUTAAS IN) – Q2FY27 Result Update – Long term growth outlook intact – BUY
Published on 27 Oct 2026
We remain positive on Acutaas’ growth outlook, supported by the ramp-up of the Fermion contract, commercialisation of four additional CDMO molecules in H2FY27 and an increasing contribution from Battery Chemicals. Management upgraded its revenue growth guidance to 30% from 25% earlier and guided for an EBITDA margin of 38–40%. These growth drivers position the company to deliver sustained earnings growth over the medium term.
At the current market price, the stock trades at 48x FY28E EPS. We value the stock at 53x Sep’29E EPS, arriving at a target price of INR4,693, and maintain our ‘Buy’ rating
